Drug Information

Drug General Information
Drug ID
D0B7VK
Former ID
DIB002318
Drug Name
Tifacogin
Synonyms
LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron
Drug Type
Small molecular drug
Indication Sepsis [ICD9: 995.91; ICD10:A40, A41] Phase 3 [526665]
Company
GD Searle & Co; Chiron
Structure
Download
2D MOL

3D MOL
Formula
C12H13NS
CAS Number
CAS 148883-56-1
PubChem Compound ID
961320
Target and Pathway
Target(s) Tissue factor pathway inhibitor Target Info Inhibitor [526665]
KEGG Pathway Complement and coagulation cascades
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Blood coagulation
Pathway Interaction Database Syndecan-4-mediated signaling events
Reactome Extrinsic Pathway of Fibrin Clot Formation
WikiPathways Complement and Coagulation Cascades
Integrated Breast Cancer Pathway
Formation of Fibrin Clot (Clotting Cascade)
References
Ref 526665Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
Ref 526665Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.